{
  "id": 9147449,
  "title": "Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026",
  "url": "https://urgent.news/2026/09/22/takeda-highlights-late-stage-oncology-pipeline-progress-and-solid",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-22T13:30:41.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/takeda-highlights-late-stage-oncology-pipeline-progress-and-solid-tumor-portfolio-research-led-by-late-breaking-phase-3-arcotatug-tavatecan-tak-921-data-at-esmo-2026"
  },
  "original_language": "en",
  "account": null,
  "summary": "Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric Cancer TAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLC Takeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}